Mangoceuticals, Gross Profit from 2010 to 2025

MGRX Stock

4.46 0.11 2.53%

Mangoceuticals, Common Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 299.3 K in 2025. Gross Profit is the profit Mangoceuticals, Common Stock makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

380 K

Current Value

299.3 K

Quarterly Volatility

149.3 K

Credit Downgrade

Yuan Drop

Covid

Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.4 K, Interest Expense of 14.4 K or Selling General Administrative of 3.2 M, as well as many indicators such as Price To Sales Ratio of 9.61, Dividend Yield of 0.14 or PTB Ratio of 0.36. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.

Check out the analysis of Mangoceuticals, Common Correlation against competitors.

Latest Mangoceuticals, Common's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Mangoceuticals, Common Stock over the last few years. Gross profit is a required income statement account that reflects total revenue of Mangoceuticals, Common Stock minus its cost of goods sold. It is profit before Mangoceuticals, Common operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Mangoceuticals, Common's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 379.96 K

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Mangoceuticals, Gross Profit Regression Statistics

	Arithmetic Mean	73,364
	Geometric Mean	10,910
	Coefficient Of Variation	203.50
	Mean Deviation	111,336
	Median	4,850
	Standard Deviation	149,297
	Sample Variance	22.3B
	Range	426.7K
	R-Value	0.66
	Mean Square Error	13.6B
	R-Squared	0.43
	Significance	0.01
	Slope	20,569
	Total Sum of Squares	334.3B

Mangoceuticals, Gross Profit History

	2025	299.3 K
	2024	380 K
	2023	431.5 K

Other Fundumenentals of Mangoceuticals, Common

Gross Profit Margin

Mangoceuticals, Common Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Accounts Payable	Property Plant Equipment	Intangible Assets
Total Assets		1.0	0.76	0.33	-0.94	0.99	0.66	0.62	-0.01	0.72	0.68	0.7	-0.46	0.73	-0.95	-0.95
Total Stockholder Equity	1.0		0.75	0.34	-0.94	0.99	0.65	0.61	-0.02	0.71	0.67	0.7	-0.47	0.73	-0.95	-0.95
Net Tangible Assets	0.76	0.75		-0.33	-0.88	0.85	0.97	0.95	0.63	0.9	0.96	0.86	0.17	0.81	-0.69	-0.69
Net Debt	0.33	0.34	-0.33		-0.02	0.21	-0.43	-0.45	-0.93	-0.33	-0.42	-0.1	-0.98	-0.23	-0.37	-0.37
Retained Earnings	-0.94	-0.94	-0.88	-0.02		-0.95	-0.81	-0.78	-0.26	-0.89	-0.85	-0.69	0.15	-0.91	0.86	0.86
Total Liab	0.99	0.99	0.85	0.21	-0.95		0.76	0.72	0.13	0.78	0.77	0.79	-0.36	0.76	-0.93	-0.93
Net Invested Capital	0.66	0.65	0.97	-0.43	-0.81	0.76		1.0	0.72	0.93	0.99	0.87	0.28	0.82	-0.53	-0.53
Short Long Term Debt	0.62	0.61	0.95	-0.45	-0.78	0.72	1.0		0.72	0.94	0.99	0.86	0.3	0.82	-0.46	-0.46
Total Current Assets	-0.01	-0.02	0.63	-0.93	-0.26	0.13	0.72	0.72		0.57	0.68	0.45	0.84	0.42	0.07	0.07
Capital Stock	0.72	0.71	0.9	-0.33	-0.89	0.78	0.93	0.94	0.57		0.98	0.73	0.21	0.97	-0.55	-0.55
Net Working Capital	0.68	0.67	0.96	-0.42	-0.85	0.77	0.99	0.99	0.68	0.98		0.82	0.27	0.9	-0.53	-0.53
Short Term Debt	0.7	0.7	0.86	-0.1	-0.69	0.79	0.87	0.86	0.45	0.73	0.82		-0.08	0.56	-0.57	-0.57
Common Stock	-0.46	-0.47	0.17	-0.98	0.15	-0.36	0.28	0.3	0.84	0.21	0.27	-0.08		0.14	0.49	0.49
Accounts Payable	0.73	0.73	0.81	-0.23	-0.91	0.76	0.82	0.82	0.42	0.97	0.9	0.56	0.14		-0.58	-0.58
Property Plant Equipment	-0.95	-0.95	-0.69	-0.37	0.86	-0.93	-0.53	-0.46	0.07	-0.55	-0.53	-0.57	0.49	-0.58		1.0
Intangible Assets	-0.95	-0.95	-0.69	-0.37	0.86	-0.93	-0.53	-0.46	0.07	-0.55	-0.53	-0.57	0.49	-0.58	1.0

Click cells to compare fundamentals

About Mangoceuticals, Common Financial Statements

Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	380 K	299.3 K
Gross Profit Margin	0.80	0.52

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC